| Title: |
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors. |
| Authors: |
Hoogenkamp, Denise S., de Wit–van der Veen, Linda J., Huizing, Daphne M. V., Tesselaar, Margot E. T., van Leeuwaarde, Rachel S., Stokkel, Marcel P. M., Lam, Marnix G. E. H., Braat, Arthur J. A. T. |
| Source: |
Current Oncology Reports; May2024, Vol. 26 Issue 5, p551-561, 11p |
| Abstract: |
Purpose of Review: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. Recent Findings: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery. Summary: There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Oncology Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
